Minoryx's leriglitazone (Nezglyal) won EU backing after two prior rejections, while CHMP rejected Zevra's arimoclomol (Meplyffa).
Minoryx Therapeutics finally scored backing from EU regulators for its neurological drug that’s faced multiple hurdles. Meanwhile, Zevra’s rare disease drug got a setback in …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C - Zevra Ther
Minoryx obtiene el visto bueno de la EMA para su f�rmaco estrella
AbelZeta Receives FDA Clearance of Registrational Phase II Trial for C-CAR168 in Refractory Lupus Nephritis
Minoryx consigue la validación de su fármaco en la Agencia Europea de Medicamentos
Another setback for Ipsen's Albireo portfolio as Bylvay flunks phase 3 trial
On 4th try, Outlook scores FDA nod for reformulated version of Roche's Avastin for AMD
MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal - MapLight Therapeut
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
